Shafin Kalyan, Shafin Kalyan, Founder at Veridata Health, shared Mayo Clinic Platform’s post on LinkedIn, adding:
“Proud to be part of the newest cohort of Mayo Clinic Platform.
Every cancer program finds patients who need a diagnostic workup: an abnormal result, a positive screen, a suspicious image.
The hard part is what happens next. A referral is not an order, an order is not a completed test, and a completed test is not a documented answer.
That’s the gap we’re building for.
Veridata Health builds the grid for precision medicine: software that closes the loop between laboratory data, AI models and clinical teams, so every result leads to a reviewed next step.
Each step runs on the institution’s rules, with a named owner and a record of what happened.
Through the Platform Accelerate program, we aim to further evaluate and scale our approach to diagnostic follow-through, leveraging Mayo Clinic Platform resources as part of the cohort.
Congratulations to all the companies joining us, and thank you to the Mayo Clinic Platform team.
Meet the cohort: October 2026. Meet the Newest Cohort of Innovative Health Tech Startups.”
Quoting Mayo Clinic Platform’s post:
“Time to meet the October 2026 Cohort of Mayo Clinic Platform Accelerate!
These innovative health tech companies will leverage advanced technologies, Mayo Clinic expertise, and de-identified clinical data to build and scale impactful digital health solutions as part of our 30-week or multiyear Accelerate program pathways.”
Other articles about Mayo Clinic Platform and precision medicine on OncoDaily.